Therapeutics case studies
How we maximise the value of our clients' development approach while reducing costs and timelines
Learn more on how we bring life changing therapies to market.
Providing empirically based guidance and built-to-spec models and solutions across every phase of clinical research and lifecycle management for therapeutic development.
Quantifying the impact of SDOH
Understanding Social Determinants of Health (SDOH) is key to addressing disparities and improving outcomes in Type 2 Diabetes. While factors like diet and access to care are known, quantifying their impact on diagnosis, treatment initiation, and adherence remains an emerging focus.
Immune assay for thyroid diseases
A top medical device maker partnered with ICON to validate a new immune assay. The study aimed to collect serum samples from up to 760 U.S. patients with various thyroid and autoimmune conditions to demonstrate assay performance.
Complex phase 1 obesity study
ICON was once again selected as a partner to conduct a phase 1 study in individuals who are overweight or have obesity, evaluating the safety and tolerability of a new subcutaneous GLP-1 and amylin peptide formulation.
Proactive patient retention strategy in a GLP-1 RA trial
Explore how ICON successfully supported a sponsor’s cardiovascular outcome trial for a GLP-1 receptor agonist with 9,900+ patients with type 2 diabetes and maintained a retention rate of 97% over 7 years.
High-volume medical imaging to support a MASH clinical trial
A pivotal phase 3 randomised, double-blind study to improve MASH and reduce progression to cirrhosis and/or hepatic decompensation, with high volumes of scans across two imaging modalities.